export const NOVARTIS_CONVERSATION = [
    {
        id: 1,
        speaker: {
            value: 'Sarah',
            label: 'Sarah (Female)',
        },
        text: "Good morning Dr. Patel, thank you for taking the time to meet with me today. I'm Sarah from Novartis.",
    },
    {
        id: 2,
        speaker: {
            value: 'DrPatel',
            label: 'Dr. Patel (Male)',
        },
        text: 'Good morning Sarah. I’m always happy to learn more about new treatments.',
    },
    {
        id: 3,
        speaker: {
            value: 'Sarah',
            label: 'Sarah (Female)',
        },
        text: 'Great! Today, I’d like to talk to you about one of our newest treatments for chronic heart failure, Entresto.',
    },
    {
        id: 4,
        speaker: {
            value: 'DrPatel',
            label: 'Dr. Patel (Male)',
        },
        text: 'Ah yes, I’ve heard a bit about Entresto. How does it compare to other treatments currently available?',
    },
    {
        id: 5,
        speaker: {
            value: 'Sarah',
            label: 'Sarah (Female)',
        },
        text: "Entresto is a first-in-class medication combining two active ingredients, sacubitril and valsartan. It’s been shown to reduce the risk of cardiovascular death and hospitalization due to heart failure, offering a significant improvement over traditional ACE inhibitors.",
    },
    {
        id: 6,
        speaker: {
            value: 'DrPatel',
            label: 'Dr. Patel (Male)',
        },
        text: 'Interesting. And what kind of patients would you recommend Entresto for?',
    },
    {
        id: 7,
        speaker: {
            value: 'Sarah',
            label: 'Sarah (Female)',
        },
        text: 'Entresto is indicated for patients with chronic heart failure with reduced ejection fraction. It’s ideal for those who are not getting optimal results from ACE inhibitors or ARBs, and for patients at high risk of hospitalization.',
    },
    {
        id: 8,
        speaker: {
            value: 'DrPatel',
            label: 'Dr. Patel (Male)',
        },
        text: 'What about side effects? Are there any concerns I should be aware of?',
    },
    {
        id: 9,
        speaker: {
            value: 'Sarah',
            label: 'Sarah (Female)',
        },
        text: "The most common side effects are hypotension, hyperkalemia, and renal impairment. However, studies have shown that most patients tolerate it well, and the benefits often outweigh these risks, especially in patients with a high risk of cardiac events.",
    },
    {
        id: 10,
        speaker: {
            value: 'DrPatel',
            label: 'Dr. Patel (Male)',
        },
        text: 'That sounds promising. Do you have any clinical data to support its efficacy?',
    },
    {
        id: 11,
        speaker: {
            value: 'Sarah',
            label: 'Sarah (Female)',
        },
        text: "Yes, absolutely. The PARADIGM-HF trial is the key study. It demonstrated that Entresto reduced the risk of death from cardiovascular causes by 20%, and the risk of first heart failure hospitalization by 21%, compared to enalapril.",
    },
    {
        id: 12,
        speaker: {
            value: 'DrPatel',
            label: 'Dr. Patel (Male)',
        },
        text: "Those are impressive results. I’ll definitely consider this for my patients. What about dosing?",
    },
    {
        id: 13,
        speaker: {
            value: 'Sarah',
            label: 'Sarah (Female)',
        },
        text: "Entresto is typically started at a dose of 49/51 mg twice daily, but it can be titrated up to 97/103 mg twice daily depending on the patient’s tolerance and needs.",
    },
    {
        id: 14,
        speaker: {
            value: 'DrPatel',
            label: 'Dr. Patel (Male)',
        },
        text: "And how would I transition a patient currently on an ACE inhibitor to Entresto?",
    },
    {
        id: 15,
        speaker: {
            value: 'Sarah',
            label: 'Sarah (Female)',
        },
        text: "Good question. There should be a 36-hour washout period between discontinuing the ACE inhibitor and starting Entresto to reduce the risk of angioedema.",
    },
    {
        id: 16,
        speaker: {
            value: 'DrPatel',
            label: 'Dr. Patel (Male)',
        },
        text: "Got it. I’ll definitely keep that in mind. Is there anything else I should know?",
    },
    {
        id: 17,
        speaker: {
            value: 'Sarah',
            label: 'Sarah (Female)',
        },
        text: "We’re here to support you and your patients with any resources you might need, including educational materials and patient support programs to ensure adherence and outcomes.",
    },
    {
        id: 18,
        speaker: {
            value: 'DrPatel',
            label: 'Dr. Patel (Male)',
        },
        text: "That’s helpful. I’ll reach out if I have any further questions. Thanks for the information, Sarah.",
    },
    {
        id: 19,
        speaker: {
            value: 'Sarah',
            label: 'Sarah (Female)',
        },
        text: "Thank you, Dr. Patel. I’ll follow up with some additional materials, and feel free to contact me anytime if you need more information.",
    },
    {
        id: 20,
        speaker: {
            value: 'DrPatel',
            label: 'Dr. Patel (Male)',
        },
        text: 'Will do. Have a great day!',
    },
    {
        id: 21,
        speaker: {
            value: 'Sarah',
            label: 'Sarah (Female)',
        },
        text: 'You too, Dr. Patel.',
    },
];
